Cheng ST, Mak EP, Lau RW, Ng NS, Lam LC
GLOW Peptide Dosage Chart A standard 70 mg GLOW vial contains three peptides in fixed mass ratios: 50 mg GHK-Cu, 10 mg BPC-157, and 10 mg full-length TB-4
It suggests the drug reached the brain and affected disease-relevant pathways, but that timing, magnitude, delivery, or patient selection were insufficient to overcome established neurodegeneration when used as a stand-alone therapy
This can reduce side effects while maintaining or improving efficacy a principle well-established in pharmacology
They are not approved for human or veterinary use by the FDA, EMA, or any other regulatory authority
Whether these effects occur because BPA is directly interacting with the ion channels on bipolar cells themselves 26 or indirectly altering neuronal activity via intracellular pathways and/or non-genomic estrogenic signaling 88 is not known, though our data supports both hypotheses